公开(公告)号：US20210145879A1

公开(公告)日：2021-05-20

申请号：US16953879

申请日：2020-11-20

申请人： NantKwest, Inc.

发明人： John H. Lee ,  Laurent H. Boissel ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  C07K14/735 ,  C07K16/28 ,  C12N5/0783

摘要： A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGFβ inhibitor and/or IL-12, where the recombinant cell is gamma (γ)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.

公开(公告)号：US20200038441A1

公开(公告)日：2020-02-06

申请号：US16529029

申请日：2019-08-01

申请人： NANTKWEST, INC.

发明人： Hans G. Klingemann ,  Laurent H. Boissel ,  John H. Lee ,  Nathan T. Schumer

IPC分类号： A61K35/17 ,  C12N15/62 ,  A61P35/02 ,  C12N15/85 ,  C07K14/705 ,  C07K14/82 ,  C07K14/55 ,  C07K14/725 ,  C07K14/54 ,  A61K9/00

摘要： Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.

公开(公告)号：US20210169931A1

公开(公告)日：2021-06-10

申请号：US17115360

申请日：2020-12-08

申请人： NantKwest, Inc.

发明人： Laurent H. Boissel ,  John H. Lee ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/715 ,  C07K14/47

摘要： Compositions and methods are provided for generating a clonal population of transfected eukaryotic cells derived from a single cell. The method includes transfecting a population of eukaryotic cells with a multi-cistronic nucleic acid vector followed by non-antibiotic selection and characterization of the selected cells. The multi-cistronic nucleic acid vector encodes a selection element which may be an autocrine protein, miRNA, and/or shRNA.

公开(公告)号：US10960024B2

公开(公告)日：2021-03-30

申请号：US16529029

申请日：2019-08-01

申请人： NANTKWEST, INC.

发明人： Hans G. Klingemann ,  Laurent H. Boissel ,  John H. Lee ,  Nathan T. Schomer

IPC分类号： C07K16/32 ,  C07K16/28 ,  C07K14/705 ,  A61K35/17 ,  C12N15/62 ,  A61P35/02 ,  C12N15/85 ,  A61K9/00 ,  C07K14/82 ,  C07K14/55 ,  C07K14/725 ,  C07K14/54

摘要： Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.

公开(公告)号：US11230699B2

公开(公告)日：2022-01-25

申请号：US16775111

申请日：2020-01-28

申请人： NANTKWEST, INC.

发明人： John H. Lee ,  Laurent H. Boissel ,  Hans G. Klingemann

IPC分类号： A61K48/00 ,  C07H21/04 ,  C12N5/0783 ,  C07K16/32 ,  C07K14/735 ,  C07K14/55 ,  C07K14/54 ,  C07K14/71 ,  A61K35/17 ,  A61P35/00 ,  A61K45/06 ,  C07K16/28 ,  C12N15/00

摘要： Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

公开(公告)号：US20210230547A1

公开(公告)日：2021-07-29

申请号：US16775111

申请日：2020-01-28

申请人： NANTKWEST, INC.

发明人： John H. Lee ,  Laurent H. Boissel ,  Hans G. Klingemann

IPC分类号： C12N5/0783 ,  C07K16/28 ,  C07K16/32 ,  C07K14/735 ,  C07K14/55 ,  C07K14/54 ,  C07K14/71 ,  A61K35/17 ,  A61P35/00 ,  A61K45/06

摘要： Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

公开(公告)号：US20210106619A1

公开(公告)日：2021-04-15

申请号：US17024155

申请日：2020-09-17

申请人： NantKwest, Inc.

发明人： John H. Lee

IPC分类号： A61K35/17 ,  A61K49/00 ,  C07K14/725 ,  C07K14/705

摘要： Compositions of luminescence labeled activated natural killer (aNK) cells are utilized in methods of in vivo bioluminescence imaging (BLI) for assaying and identifying genetically modified NK cells capable of targeting selected anatomical locations (e.g., bone and/or brain) or targeting selected diseased cells at selected sites.

公开(公告)号：US20200093863A1

公开(公告)日：2020-03-26

申请号：US16708082

申请日：2019-12-09

申请人： NANTKWEST, INC.

发明人： Hans G. Klingemann ,  Laurent H. Boissel ,  John H. Lee ,  Nathan T. Schumer

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  A61P35/02 ,  C07K14/55 ,  C12N15/85 ,  A61K9/00 ,  C07K14/54 ,  C07K14/82 ,  C12N15/62

摘要： Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.